A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal

June 20, 2018
Pulmonary Hypertension, Pulmonary
Principal Investigator: Rana L Awdish, MD
Pulmonary Hypertension, Pulmonary Arterial Hypertension, PH, PAH, Hypertension, Pulmonary, Atrial Hypertension
Accepting Participants